Instructional BiologyIdeas shaping the next biological era.
Company perspectives, platform explainers, and public milestones — written for scientists, partners, and curious readers. Some of these pieces are conceptual, describing where we think the field is heading and why. Others are grounded in industry data, like the economics behind Patent Cliff 2.0. All of them carry the same standard: research-stage framing, no efficacy claims we can't stand behind, and a clear line between what we've built and what we're still building toward.
How Lasers Kill Viruses
No heat, no chemicals, no ionizing radiation. How ultrashort laser pulses inactivate viruses by shaking their capsid apart — the physics of impulsive stimulated Raman scattering, published since 2007.
Read the perspective →Digital Twins: A Model That Learns With You
A responsible digital twin isn't a science-fiction duplicate. It's an evolving, evidence-bounded model that could one day help researchers understand change over time.
Read the perspective →Bespoke Therapeutics: A Paradigm Shift Is Here
The next era of medicine isn't one more molecule for one more target. It's therapeutics designed around the logic of an individual system, not a population average.
Read the perspective →No One Is the Same: Medicine That Adapts to You
Wearables already track how your body responds, minute to minute. Why the next frontier is treatment informed by that response — inside a clinician-authorized envelope, not a fixed dose that ignores it.
Read the perspective →The Latest Innovations in Biomanufacturing: Introducing MHFBP
The pathogen-safety-versus-structure tradeoff has shaped biomanufacturing for decades. Why we think it was never actually fixed — and what MHFBP does differently.
Read the perspective →Medicine, Made For You
The average patient does not exist. Why treating everyone against a population average leaves real signal on the table, and what a more individualized approach could look like.
Read the perspective →In Silico: Testing Biology Before You Touch It
Every physical experiment costs time, tissue, and money. What in silico modeling actually means, and why the best experiment is often the one you never had to run.
Read the perspective →Why Pills Are Dead: Surviving Patent Cliff 2.0
Between now and 2030, independent estimates put $200–400 billion in branded-drug revenue at risk as roughly 190–200 drugs lose exclusivity. Why the deeper opportunity isn't replacing aging molecules — it's a reusable way of understanding biology itself.
Read the perspective →A New Class of Therapeutics: The Thermosensitive Peptidome
Most biological signaling molecules never survive legacy manufacturing. What the Thermosensitive Peptidome is, why heat destroys it, and why preserving it — not replacing it — is the harder engineering problem.
Read the perspective →The Cost of Learning Too Late
Clinical attrition is measured in capital, but its deeper burden is carried in time, uncertainty, participant effort, and delayed progress. Why closing that gap is worth building for.
Read the perspective →